<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117424</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-CAMPUS</org_study_id>
    <nct_id>NCT05117424</nct_id>
  </id_info>
  <brief_title>CArdioMetabolism and Atherosclerotic PlaqUe progreSsion</brief_title>
  <acronym>CAMPUS</acronym>
  <official_title>The Impact of Cardiometabolic Factors on Coronary Artery and Cardiovascular Diseases: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systematic metabolic diseases are closely related to prevalence and progression of&#xD;
      atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery&#xD;
      disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity,&#xD;
      chronic kidney disease and hyperuricemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CArdioMetabolism and Atherosclerotic PlaqUe progreSsion (CAMPUS) study is a single center,&#xD;
      prospective cohort study to investigate the impact of cardiometabolic factors on coronary&#xD;
      diseases. This study consecutively enrolls patients with coronary artery diseases&#xD;
      complicatied with metabolic abnormalities, including diabetes, prediabetes, obesity, chronic&#xD;
      kidney disease and hyperuricemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Coronary plaque progression</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by coronary angiography and QCA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary lesion severity</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by coronary angiography and QCA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary plaque characteristics</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by intravascular imaging (IVUS or OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The incidence of MACCE (major adverse cardio and cerebral vascular events), lesion associated events (target lesion myocardial infarction, target lesion faliure, target vessel revascularization, etc.)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diabetic complications</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Prevalence of diabetic complications, including peripheral artery disease, retinopathy, nephropathy, encephalopathy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycated modifications of lipoproteins</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Glycated modifications of lipoproteins in patients, such as ApoA-I glycation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipoprotein function assessment</measure>
    <time_frame>up to 2 years</time_frame>
    <description>HDL functions, including reverse cholesterol transport assessed by cholesterol efflux capacity, anti-inflammatory function, and anti-oxidation function</description>
  </other_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Dyslipidemias</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to determine apoA-I glycation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study is a single-center cohort study. Patients with type 2 diabetes and suspected&#xD;
        coronary artery disease undergone coronary angiography at Ruijin Hospital, Shanghai, China&#xD;
        are consecutively enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Type 2 diabetes diagnosed by one of the following criteria:&#xD;
&#xD;
        HbA1c &gt;/= 6.5% Fasting plasma glucose &gt;/= 7.0 mmol/l (confirmed) 2h plasma glucose value&#xD;
        during OGTT &gt;/= 11.1 mmol/l Already receiving glucose-lowering agents&#xD;
&#xD;
          -  Prediabetes&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
&#xD;
          -  Hyperuricemia&#xD;
&#xD;
          -  Receiving coronary angiography for clinically suspected coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe liver failure (Child-Pugh grade B to C)&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt; 60g/L)&#xD;
&#xD;
          -  Familial hypercholesterolemia&#xD;
&#xD;
          -  Active malignant tumor&#xD;
&#xD;
          -  Active autoimmune diseases on corticosteroids&#xD;
&#xD;
          -  Acute or chronic infection&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Lu, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital, Shanghai Jiaotong School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fenghua Ding, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital, Shanghai Jiaotong School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruiyan Zhang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital, Shanghai Jiaotong School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoqun Wang, M.D., Ph.D.</last_name>
    <phone>+86 21 13651839760</phone>
    <email>xiaoqun_wang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuo Feng, M.D.</last_name>
    <phone>+86 21 15921388296</phone>
    <email>fengshuorv@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Li, BS</last_name>
      <phone>0086 021 64370045</phone>
      <email>ruijincrc@126.com</email>
    </contact>
    <investigator>
      <last_name>Ruiyan Zhang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Lu, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fenghua Ding, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoqun Wang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Shen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lili Liu, M.E.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuo Feng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>RUIYAN ZHANG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

